The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy.
about
High-throughput screening to enhance oncolytic virus immunotherapySystematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanomaMouse IP-10 Gene Delivered by Folate-modified Chitosan Nanoparticles and Dendritic/tumor Cells Fusion Vaccine Effectively Inhibit the Growth of Hepatocellular Carcinoma in MiceAntitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo.Oncolytic viruses: focusing on the tumor microenvironment.Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization.
P2860
The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The addition of recombinant va ...... ne escape and systemic anergy.
@ast
The addition of recombinant va ...... ne escape and systemic anergy.
@en
type
label
The addition of recombinant va ...... ne escape and systemic anergy.
@ast
The addition of recombinant va ...... ne escape and systemic anergy.
@en
prefLabel
The addition of recombinant va ...... ne escape and systemic anergy.
@ast
The addition of recombinant va ...... ne escape and systemic anergy.
@en
P2093
P2860
P356
P1433
P1476
The addition of recombinant va ...... ne escape and systemic anergy.
@en
P2093
C E Monken
C R de Vries
E C Lattime
P2860
P2888
P304
P356
10.1038/CGT.2015.2
P577
2015-01-30T00:00:00Z